These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20583861)

  • 1. Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes).
    Kotthaus J; Steinmetzer T; van de Locht A; Clement B
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):115-22. PubMed ID: 20583861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.
    Riggs JR; Kolesnikov A; Hendrix J; Young WB; Shrader WD; Vijaykumar D; Stephens R; Liu L; Pan L; Mordenti J; Green MJ; Sukbuntherng J
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2224-8. PubMed ID: 16458507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of factor Xa inhibitors and their prodrugs.
    Song Y; Clizbe L; Bhakta C; Teng W; Wong P; Huang B; Tran K; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Jan; 13(2):297-300. PubMed ID: 12482444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
    Reeh C; Wundt J; Clement B
    J Med Chem; 2007 Dec; 50(26):6730-4. PubMed ID: 18052320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
    Weller T; Alig L; Beresini M; Blackburn B; Bunting S; Hadváry P; Müller MH; Knopp D; Levet-Trafit B; Lipari MT; Modi NB; Müller M; Refino CJ; Schmitt M; Schönholzer P; Weiss S; Steiner B
    J Med Chem; 1996 Aug; 39(16):3139-47. PubMed ID: 8759635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
    Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-substituted bis-C-alkyloxadiazolones as dual effectors: efficient intermediates to amidoximes or amidines and prodrug candidates of potent antimalarials.
    Degardin M; Wein S; Durand T; Escale R; Vial H; Vo-Hoang Y
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5233-6. PubMed ID: 19643611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.
    Uchida M; Okazaki K; Mukaiyama H; Isawa H; Kobayashi H; Shiohara H; Muranaka H; Kai Y; Kikuchi N; Takeuchi H; Yokoyama K; Tsuji E; Ozawa T; Hoyano Y; Koizumi T; Misawa K; Hara K; Nakano S; Murakami Y; Okuno H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4682-7. PubMed ID: 18667303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
    Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
    Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New prodrugs of the antiprotozoal drug pentamidine.
    Kotthaus J; Kotthaus J; Schade D; Schwering U; Hungeling H; Müller-Fielitz H; Raasch W; Clement B
    ChemMedChem; 2011 Dec; 6(12):2233-42. PubMed ID: 21984033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines.
    Clement B
    Drug Metab Rev; 2002 Aug; 34(3):565-79. PubMed ID: 12214667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
    Clement B; Lopian K
    Drug Metab Dispos; 2003 May; 31(5):645-51. PubMed ID: 12695354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrochemical and mARC-catalyzed enzymatic reduction of para-substituted benzamidoximes: consequences for the prodrug concept "amidoximes instead of amidines".
    Bauch E; Reichmann D; Mendel RR; Bittner F; Manke AM; Kurz P; Girreser U; Havemeyer A; Clement B
    ChemMedChem; 2015 Feb; 10(2):360-7. PubMed ID: 25512261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
    West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
    Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
    J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines.
    Kotthaus J; Hungeling H; Reeh C; Kotthaus J; Schade D; Wein S; Wolffram S; Clement B
    Bioorg Med Chem; 2011 Mar; 19(6):1907-14. PubMed ID: 21345682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
    Schweinitz A; Dönnecke D; Ludwig A; Steinmetzer P; Schulze A; Kotthaus J; Wein S; Clement B; Steinmetzer T
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1960-5. PubMed ID: 19250826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
    Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
    [No Abstract]   [Full Text] [Related]  

  • 20. The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
    Gruenewald S; Wahl B; Bittner F; Hungeling H; Kanzow S; Kotthaus J; Schwering U; Mendel RR; Clement B
    J Med Chem; 2008 Dec; 51(24):8173-7. PubMed ID: 19053771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.